NCT05517525View on ClinicalTrials.gov

A Study to Evaluate the Pharmacokinetics (PK) and Safety of a Single Dose of Brensocatib in Participants With Normal Hepatic Function and Participants With Hepatic Impairment

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

October 4, 2022

Primary Completion Date

June 1, 2023

Study Completion Date

June 1, 2023

Conditions
Hepatic Impairment
Interventions
DRUG

Brensocatib

Oral tablet.

Trial Locations (3)

32809

USA003, Orlando

78215

USA001, San Antonio

92377

USA002, Rialto

All Listed Sponsors
lead

Insmed Incorporated

INDUSTRY